BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial products for multi-drug resistant (MDR) infections, announced that all proposals by the Board of Directors were approved by shareholders at the Annual General Meeting held on April 30, 2026.
The company, headquartered in Basel, Switzerland, reported that shareholders approved the 2025 Annual Report, annual financial statements, consolidated financial statements, and acknowledged the Auditors' reports. Additionally, the re-election of Seng Chin Mah as Chairman of the Board of Directors was ratified, along with the re-election of David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Ms. Simona Skerjanec was elected as a new member of the Board of Directors, replacing Dr. William Jenkins, who stepped down after his term.
Shareholders also approved the maximum aggregate compensation for the Board of Directors for the term until the 2027 AGM and for the Executive Committee for the financial year 2027. The minutes and relevant documents, including the Annual Report, are available on the company's website at this link and the AGM details at this link.
Dr. Seng Chin Mah, Chairman of the Board, expressed gratitude to shareholders for their continued trust and support. He highlighted the company's recent achievement of First Patient First Visit (FPFV) for the global Phase 3 trial of BV100, a treatment for Acinetobacter baumannii infections. "Having achieved FPFV for the global BV100 Phase 3 trial, we are completely focused on eventually bringing this therapeutic option to patients in dire need. Our teams are equally determined to progress alpibectir and our preclinical pipeline with our partners," Dr. Mah said. He also thanked Dr. William Jenkins for his contributions and welcomed Ms. Simona Skerjanec to the Board.
BioVersys is developing BV100 for nosocomial infections caused by Acinetobacter baumannii, a multi-drug resistant pathogen that poses a serious threat in healthcare settings. The company's pipeline also includes alpibectir, a candidate for tuberculosis currently in Phase 2 development in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France. Additionally, the company's preclinical pipeline leverages its two internal technology platforms: TRIC and Ansamycin Chemistry, designed to overcome resistance mechanisms and block virulence production.
The approval of all board proposals signals strong shareholder confidence in BioVersys's strategic direction and its mission to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections. The company's focus on multi-drug resistant bacteria is critical as antimicrobial resistance continues to rise globally, threatening to undermine decades of medical progress. By advancing novel antibacterial products, BioVersys aims to provide new options for patients with serious infections that are increasingly difficult to treat with existing antibiotics.
